Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) Equity Ratio (2018 - 2025)

Historic Equity Ratio for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to 0.92.

  • Neurogene's Equity Ratio rose 1018.47% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year increase of 1018.47%. This contributed to the annual value of 0.92 for FY2024, which is 1061.14% up from last year.
  • Per Neurogene's latest filing, its Equity Ratio stood at 0.92 for Q3 2025, which was up 1018.47% from 0.92 recorded in Q2 2025.
  • Neurogene's Equity Ratio's 5-year high stood at 0.93 during Q1 2025, with a 5-year trough of 0.83 in Q1 2023.
  • For the 3-year period, Neurogene's Equity Ratio averaged around 0.87, with its median value being 0.86 (2024).
  • Within the past 5 years, the most significant YoY rise in Neurogene's Equity Ratio was 1061.14% (2024), while the steepest drop was 30.13% (2024).
  • Over the past 3 years, Neurogene's Equity Ratio (Quarter) stood at 0.84 in 2023, then grew by 10.61% to 0.92 in 2024, then fell by 0.21% to 0.92 in 2025.
  • Its Equity Ratio was 0.92 in Q3 2025, compared to 0.92 in Q2 2025 and 0.93 in Q1 2025.